News coverage about IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) has trended somewhat positive on Wednesday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IntelliPharmaCeutics Intl earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news headlines about the company an impact score of 48.0202892845246 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several research firms have commented on IPCI. Maxim Group set a $2.00 price target on shares of IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a research note on Friday, February 9th. HC Wainwright set a $3.00 price target on shares of IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a research note on Monday, February 12th. Finally, Zacks Investment Research downgraded shares of IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. IntelliPharmaCeutics Intl has a consensus rating of “Hold” and an average price target of $2.53.
IntelliPharmaCeutics Intl (NASDAQ:IPCI) traded down $0.01 during mid-day trading on Wednesday, hitting $0.64. 118,100 shares of the company’s stock traded hands, compared to its average volume of 451,594. The stock has a market capitalization of $22.56, a P/E ratio of -2.21 and a beta of 1.06. IntelliPharmaCeutics Intl has a 52-week low of $0.61 and a 52-week high of $2.92.
WARNING: This story was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3228958/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-intellipharmaceutics-intl-ipci-share-price.html.
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.